Hyderabad, Jun 8 : Dr G Satheesh Reddy, Secretary, Department of Defence R&D, and Chairman, Defence Research and Development Organization (DRDO) has said that 2-DG effectively inhibits SARS-CoV-2 growth in patients due to its unique mechanism of action.

Speaking at the webinar, organized by the Federation of Telangana Chambers of Commerce and Industry-FTCCI in association with DRDO & Dr Reddy’s Laboratories, Dr Reddy said “2-DG effectively inhibits SARS-CoV-2 growth in Covid-19 patients due to its unique mechanism of action.

The drug is found safe and effective in clinical trials. Production of drug is easily scalable and it can be easily stored and distributed, ” he added.

Mr Deepak Sapra, CEO, Pharmaceutical Services & Active Ingredients (PSAI), Lead: Covid Initiatives, Dr. Reddy’s said we are proud to be associated with the 2DG program in collaboration with DRDO. This is a reaffirmation of our commitment to fighting Covid in every possible way whether it is through therapeutics or through vaccines.

We believe that 2DG will represent an important add-on therapy to the standard of care for moderate to severe category patients all over India and will Support them in their recovery from Covid.

We are very proud to be working with INMAS which is an organization under DRDO and this collaboration has given us a lot of hope that collaboration between scientific bodies under the government and the Pharmaceutical industry can be very impactful in bringing effective Healthcare solutions in India, Deepak added.(UNI)